Mariner
QNCX icon

Mariner’s Quince Therapeutics QNCX Stock Holding History

Mariner’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63
Closed -$1.28K – 3850
2026
Q1 		$1.28K Buy
+63
New +$12.6K ﹤0.01% 3540
2025
Q4 		– Sell
-612
Closed -$200K – 3754
2025
Q3 		$200K Hold
612
– – ﹤0.01% 3180
2025
Q2 		$202K Hold
612
– – ﹤0.01% 3049
2025
Q1 		$163K Hold
612
– – ﹤0.01% 3069
2024
Q4 		$229K Hold
612
– – ﹤0.01% 2888
2024
Q3 		$95.1K Buy
612
+242
+65% +$34.7K ﹤0.01% 3100
2024
Q2 		$55.6K Hold
370
– – ﹤0.01% 3036
2024
Q1 		$78.5K Hold
370
– – ﹤0.01% 2973
2023
Q4 		$77.8K Sell
370
-5
-1% -$1K ﹤0.01% 2893
2023
Q3 		$84.1K Buy
+375
New +$98K ﹤0.01% 2705

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mariner's QNCX Position: Q2 2026 in Review

Mariner sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 63 shares — an estimated $1.28K sold.

Mariner first reported a position in QNCX in Q3 2023 and held it in 10 quarters. The position peaked at $229K in Q4 2024. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Mariner reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 63 Quince Therapeutics shares in Q2 2026, an estimated $1.28K.
  • Mariner first reported a position in Quince Therapeutics in Q3 2023 and held it in 10 quarters.
  • Mariner's Quince Therapeutics position peaked at $229K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.